KRAS and neoplasm: The FET cells have an activating mutation in K-Ras, and activation of MAPK/ERK and AKT pathways (Figure 2B) in the liver metastases coupled with the suppression of growth inhibitory effects of TGF-β by Smad7 may exert a selective pressure for tumour outgrowth.